微创青光眼手术设备市场：按机制、适应症、手术方法、最终用户和分销管道 - 全球预测 2025-2030

微创青光眼手术设备市场预计到 2024 年将达到 6.1265 亿美元，到 2025 年将达到 6.4708 亿美元，到 2030 年将达到 8.578 亿美元，复合年增长率为 5.76%。

主要市场统计数据
基准年2024年	6.1265亿美元
预计2025年	6.4708亿美元
预测年份 2030	8.578亿美元
复合年增长率（%）	5.76%

简要介绍微创青光眼手术设备如何再形成整个护理领域的临床决策和程序路径

微创青光眼手术器械正在重新定义青光眼治疗途径，它提供了更具破坏性的手术替代方案，并专注于安全性、快速恢復和在临床实践中的可重复应用。近期器械创新和外科医生不断变化的偏好正在加速对治疗流程的重新评估，并吸引了眼科领域领导者、门诊手术医生和临床创新者的注意。本介绍阐述了技术进步、临床证据的累积以及医疗服务模式的不断发展如何共同塑造青光眼的采用轨迹和商业性重点。

不断发展的设备设计、护理地点的变化和付款人的期望如何融合，改写竞争动态和临床决策路径

在技​​术进步、临床证据日益增多以及医疗机构运作模式革新的推动下，微创青光眼手术设备领域正在经历变革。设备的演进已超越单点改进，需要从系统层面重新思考如何实现压力调节、如何输送设备以及如何衡量疗效，这迫使临床医生和管理人员重新评估治疗顺序和治疗路径。

对 2025 年美国关税如何重塑整个医疗设备价值链的供应链、筹资策略和商业合约进行定性评估

美国于2025年宣布的关税政策环境，对微创青光眼手术器械生态系统的参与者产生了重大的业务和策略影响。虽然关税通常被视为贸易政策槓桿，但其累积效应已波及供应链、筹资策略和商业性定价。拥有全球化采购足迹的製造商必须重新评估其供应商组合，以维持利润率并确保零件的持续供应。

细分主导的见解，解释机制、临床适应症、手术方法、医疗环境和分销动态如何决定采用和定位

细分市场层面的动态变化揭示了机制、适应症、手术方法、最终用户和分销管道如何各自塑造出製造商和医疗保健提供者必须应对的竞争和临床路径。在小梁微绕道手术中，Hydrus Microstent、Istent、Kahook Dual Blade 和 Trabectome 等特定器械的变体展现了设计差异化如何影响植入技术和术后管理，因为能够最大程度减少组织损伤并缩短手术时间的器械更容易在门诊环境中应用。

美洲、中东和非洲以及亚太地区的监管影响、商业化和临床医生采用

区域动态正在重塑不同地区的投资重点、监管参与度和商业性执行，每个地区都呈现出独特的机会和限制。在美洲，创新中心、集中的付款人互动以及高密度的门诊手术中心营造出一种有利于疗效可预测且可透过现有分销网络进行扩展的设备的环境。该地区的监管途径和报销谈判通常会奖励可靠的临床证据和基于价值的叙述。

从现有的投资组合到新兴企业主导的颠覆，不同的企业策略如何影响商业化、证据产生和竞争定位

公司层级的策略展现出各种行为，这些行为反映了风险偏好、资源频宽和策略重点的差异。许多现有的医疗设备公司专注于逐步增强其设备，扩展外科医生培训项目，并利用现有销售管道推动其在门诊和住院环境中的应用。这些现有公司通常强调产品组合整合、捆绑围手术全期服务以及支付方参与，以将医疗设备嵌入到护理路径中。

製造商、供应链领导者、临床医生和付款人可以部署实用的策略槓桿来促进采用并保护他们的营运免受政策和市场衝击。

对于寻求将洞察转化为临床应用、商业性吸引力和业务韧性方面可衡量成果的领导者来说，可行的优先事项已经浮现。製造商应优先建立模组化证据包，以同时满足临床终点和付款人相关的价值指标，同时设计培训课程，以缩短外科医生的学习曲线并促进门诊患者采用。对上市后监测和真实世界证据平台的投资将有助于增强报销论点并维护供应商的信心。

严格的多资讯来源调查方法，结合主要临床访谈、监管审查和重复检验，确保分析的可靠性

本分析所采用的调查方法是综合三个证据线索，这些证据线索来自主要相关人员研究、针对性的二次研究和系统性检验方案。主要输入包括对外科医生、手术室经理、采购主管和设备开发人员进行结构化访谈，旨在揭示他们在工作中对设备选择、手术物流和报销动态的见解。这些访谈也辅以手术工作流程和训练课程的观察，以捕捉已发表文献中可能未提及的实际整合挑战。

整合强调临床相关性、供应链弹性和有针对性的证据产生的策略要点，以确保长期采用

本执行摘要概述了定义微创青光眼手术器械的策略轮廓：跨机制的技术多样化、跨适应症和手术方法的临床应用的不断发展，以及本地化商业化策略日益重要。相关人员若能将产品设计与临床医师的实际需求结合，投资于以结果为导向的证据，并建立具有韧性和灵活性的供应链，则最有可能获得持久的价值。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

• 用于治疗青光眼的白内障和腹膜内 MIGS 联合手术的快速增加正在简化手术工作流程
• 无需每日眼药水即可持续控制眼压的药物释放型上腔微型支架的商业化
• 小梁旁路支架因其简单性和在早期青光眼中的良好安全性而越来越受到外科医生的认可
• 增加对智慧术中影像整合的投资，以提高 MIGS 设备放置的准确性和手术结果
• 扩大门诊 MIGS 治疗的报销范围，改善主要已开发市场患者的治疗可近性
• 开发下一代生物可吸收植入以减少异物反应和长期组织疤痕
• 评估 MIGS 装置与缓释性药物联合治疗以提高疗效的临床试验激增
• 新兴市场製造商正在提供具有成本竞争力的 MIGS 替代品，给现有製造商带来越来越大的价格压力。

第六章 市场洞察

• 波特五力分析
• PESTEL分析

第七章 2025年美国关税的累积影响

第八章 微创青光眼手术设备市场（依机转）

• 结膜下滤过
• 脉络膜上腔分流术
• 小梁微旁路术
  • Hydrus 微型支架
  • IStent
  • Kahook 双刃刀
  • 小梁切除术

9. 微创青光眼手术设备市场（按适应症）

• 儿童青光眼
• 原发性开放性青光眼
• 续发性青光眼

10. 微创青光眼手术设备市场（依手术方法）

• 阿贝克斯特诺
• 国际

第 11 章微创青光眼手术设备市场（按最终用户）

• 门诊手术中心
• 医院
• 眼科诊所

第 12 章微创青光眼手术设备市场（按通路）

• 离线
• 在线的

13.美洲微创青光眼手术设备市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 阿根廷

14. 欧洲、中东和非洲微创青光眼手术设备市场

• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 阿拉伯聯合大公国
• 沙乌地阿拉伯
• 南非
• 丹麦
• 荷兰
• 卡达
• 芬兰
• 瑞典
• 奈及利亚
• 埃及
• 土耳其
• 以色列
• 挪威
• 波兰
• 瑞士

15. 亚太地区微创青光眼手术设备市场

• 中国
• 印度
• 日本
• 澳洲
• 韩国
• 印尼
• 泰国
• 菲律宾
• 马来西亚
• 新加坡
• 越南
• 台湾

第十六章竞争格局

• 2024年市场占有率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Alcon Inc.
  • Ellex Medical Lasers Ltd.
  • AbbVie Inc.
  • Bausch+Lomb France SAS
  • Carl-Zeiss AG
  • Corza Ophthalmology
  • Glaukos Corporation
  • I Optima Ltd.
  • Iridex Corporation
  • iSTAR Medical
  • Johnson & Johnson Vision Care, Inc.
  • Lumenis Be Ltd.
  • New World Medical, Inc.
  • Optonol Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Sight Sciences, Inc.
  • Ziemer Ophthalmic Systems AG

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

The Minimally Invasive Glaucoma Surgery Devices Market was valued at USD 612.65 million in 2024 and is projected to grow to USD 647.08 million in 2025, with a CAGR of 5.76%, reaching USD 857.80 million by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 612.65 million
Estimated Year [2025]	USD 647.08 million
Forecast Year [2030]	USD 857.80 million
CAGR (%)	5.76%

A concise orientation to how minimally invasive glaucoma surgery devices are reshaping clinical decision-making and procedural pathways across care settings

Minimally invasive glaucoma surgery devices are redefining therapeutic pathways for glaucoma by offering less disruptive surgical alternatives that emphasize safety, faster recovery, and iterative adoption across clinical settings. Recent device innovations and evolving surgeon preferences have accelerated the re-evaluation of care algorithms, driving attention from ophthalmic leaders, ambulatory operators, and clinical innovators. This introduction frames the convergence of technological refinement, clinical evidence development, and evolving delivery models that together shape adoption trajectories and commercial priorities.

The clinical impetus for minimally invasive approaches stems from the demand to reduce reliance on chronic topical therapies, mitigate procedural risk, and expand treatment options earlier in disease pathways. As techniques have matured, stakeholders have responded by reconfiguring surgical workflows, redefining training pathways, and integrating multidisciplinary teams to manage perioperative care. Consequently, decision makers must balance device selection, surgeon training, and facility readiness alongside reimbursement realities and patient expectations.

Transitioning from procedural innovation to broader adoption requires clarity on comparative performance, ease of integration, and real-world outcomes. This introduction sets the stage for a comprehensive examination of how mechanism, indication, surgical approach, end user, and distribution dynamics influence strategic choices across manufacturers, healthcare systems, and clinical practices.

How evolving device designs, site-of-care migration, and payer expectations are converging to rewrite competitive dynamics and clinical decision pathways

The landscape for minimally invasive glaucoma surgery devices is undergoing transformative shifts driven by technological refinement, clinical evidence accumulation, and operational redesign across care sites. Device evolution has moved beyond single-point improvements to a systems-level rethinking of how pressure modulation is achieved, how devices are delivered, and how outcomes are measured, thereby prompting clinicians and administrators to reassess treatment sequencing and care pathways.

Concurrently, the locus of care is shifting as ambulatory surgery centers scale procedures that were once hospital-bound, while ophthalmic clinics expand pre- and post-operative management capabilities. This redistribution of procedure volume is supported by streamlined device profiles that reduce intraoperative complexity and postoperative follow-up demands. Alongside clinical adoption, payer dialogues have evolved to focus on value, total cost of care, and patient-reported outcomes, increasing pressure on manufacturers to demonstrate tangible improvements in safety and quality metrics.

Moreover, innovation ecosystems have broadened: partnerships between device developers, surgical training organizations, and digital-health platforms are enabling faster surgeon onboarding and outcome tracking. In parallel, a more fragmented supplier base, including nimble startups and strategic alliances with established medical device companies, is intensifying competition and accelerating feature differentiation. Together, these forces are redefining competitive advantage in a market where clinical relevance, commercial scalability, and the ability to demonstrate value to payers and providers determine long-term success.

Qualitative assessment of how the 2025 United States tariff measures reshaped supply chains, sourcing strategies, and commercial contracting across the device value chain

The policy environment introduced by United States tariffs announced in 2025 has created a material set of operational and strategic implications for participants in the minimally invasive glaucoma surgery device ecosystem. While tariffs are typically characterized as trade policy levers, their cumulative effect has rippled across supply chains, sourcing strategies, and commercial pricing decisions. Manufacturers with globalized procurement footprints have had to reassess supplier portfolios to preserve margin and ensure continuity of component availability.

Faced with increased input costs and potential delays, many device developers accelerated efforts to diversify their supplier base and identify near-shore or onshore manufacturing alternatives. This transition, however, involves lead times for qualification, regulatory transfer activities, and capital allocation decisions that can affect product timelines. For downstream stakeholders such as distributors and health systems, the tariff-driven adjustments manifested as shifts in negotiated pricing and inventory management tactics, including higher buffer stocks for critical implants and consumables.

Importantly, tariffs also influenced strategic route-to-market choices. Some manufacturers prioritized direct distribution in key regions to control margin erosion and pricing signaling, while others intensified collaboration with regional partners to mitigate tariff exposure. For clinicians and patients, the practical consequences have been uneven across settings: ambulatory centers and clinics operating on tighter procurement cycles felt pricing pressure earlier, while hospitals with longer contracting horizons absorbed changes more gradually. Overall, the 2025 tariffs catalyzed a reassessment of supply chain resilience, manufacturing location strategy, and commercial contracting practices across the value chain.

Segment-driven insights explaining how mechanism, clinical indication, surgical approach, care setting, and distribution dynamics determine adoption and positioning

Segment-level dynamics reveal how mechanism, indication, surgical approach, end user, and distribution channel each create distinct competitive and clinical pathways that manufacturers and providers must navigate. Based on Mechanism, the market is studied across Subconjunctival Filtration, Suprachoroidal Shunts, and Trabecular Micro-Bypass; within Trabecular Micro-Bypass, specific device variations such as Hydrus Microstent, IStent, Kahook Dual Blade, and Trabectome illustrate how design differentiation affects implantation technique and postoperative management. This mechanistic granularity helps explain divergent adoption curves, since devices that minimize tissue disruption and shorten operative times are more readily integrated into ambulatory settings.

Based on Indication, the market is studied across Pediatric Glaucoma, Primary Open Angle Glaucoma, and Secondary Glaucoma, and these clinical subpopulations demand distinct evidence packages and training approaches. Pediatric indications require long-term safety data and specialized instrumentation, whereas primary open angle glaucoma presentations prioritize combination therapy strategies and minimally disruptive options for earlier intervention. Secondary glaucoma cases often necessitate tailored solutions that address complex anatomy or prior surgical history, influencing device selection and surgeon preference.

Based on Surgical Approach, the market is studied across Ab Externo and Ab Interno, with the latter gaining traction due to reduced invasiveness and faster patient recovery, while ab externo techniques remain relevant for certain anatomical contexts. Based on End User, the market is studied across Ambulatory Surgery Centers, Hospital, and Ophthalmic Clinics, each with different procurement cycles, staffing models, and reimbursement frameworks that shape product positioning. Based on Distribution Channel, the market is studied across Offline and Online pathways, where digital platforms are increasingly important for clinician education, device ordering, and aftermarket support. Together, these segmentation lenses provide a multidimensional view of strategic priorities and practical constraints for product development, commercialization, and clinical adoption.

Regional implications for regulatory engagement, commercialization, and clinician adoption across Americas, Europe Middle East & Africa, and Asia-Pacific geographies

Regional dynamics are reshaping investment priorities, regulatory engagement, and commercial execution across distinct geographies, each presenting unique opportunities and constraints. In the Americas, innovation hubs, concentrated payer dialogues, and a high density of ambulatory surgery centers create an environment that favors devices which deliver predictable outcomes and can be scaled through established distribution networks. Regulatory pathways and reimbursement negotiations in this region often reward robust clinical evidence and value-based narratives.

In Europe, Middle East & Africa, fragmentation of regulatory regimes and heterogeneity in hospital procurement models require adaptive commercialization strategies. Manufacturers operating in this region benefit from modular clinical programs that can address varying evidence thresholds and from partnerships that support localized training and post-market surveillance. Price sensitivity in many markets coexists with centers of clinical excellence that serve as influential early adopters.

In Asia-Pacific, rapid capacity expansion in specialty ophthalmic centers, evolving reimbursement frameworks, and a large patient base drive diverse adoption scenarios. Local manufacturing and strategic licensing partnerships are prominent approaches to address regulatory nuances and cost expectations. Moreover, regional centers often become focal points for clinical trials and training initiatives that support broader commercialization across neighboring markets. Taken together, regional nuances demand tailored regulatory, clinical, and commercial roadmaps to optimize product uptake and long-term sustainability.

How varied company strategies - from incumbent portfolio plays to startup-led disruption - shape commercialization, evidence generation, and competitive positioning

Company-level strategies reveal a spectrum of behaviors that reflect differing risk appetites, resource endowments, and strategic priorities. Many established medical device firms focus on incremental device enhancements, scaling surgeon training programs, and leveraging existing sales channels to accelerate penetration in ambulatory and hospital settings. These incumbents often emphasize portfolio integration, bundling of perioperative services, and payer engagement to embed devices within care pathways.

Simultaneously, innovative smaller firms and startups are concentrating on disruptive device concepts, differentiated delivery mechanisms, and targeted clinical evidence to enter niche indications or surgical subsegments. These innovators frequently adopt agile development cycles, collaborate with specialized surgical centers for early feasibility studies, and pursue targeted regulatory strategies to expedite market entry. Strategic partnerships between larger firms and these innovators are increasingly common, enabling faster commercialization of novel technologies while mitigating development risk.

Across the competitive spectrum, companies prioritize three interlocking capabilities: clinical evidence generation that aligns with payer value metrics, scalable distribution and training models that lower adoption friction, and supply chain resilience that minimizes exposure to geopolitical shifts. Organizations that excel across these dimensions tend to be those that invest early in robust post-market data collection, cultivate strong clinician champions, and design commercial models that reflect the procedural economics of ambulatory and hospital environments.

Practical strategic moves manufacturers, supply chain leaders, clinicians, and payers can deploy to accelerate adoption and insulate operations from policy and market shocks

Actionable priorities emerge for leaders seeking to convert insights into measurable outcomes in clinical adoption, commercial traction, and operational resilience. Manufacturers should prioritize building modular evidence packages that address both clinical endpoints and payer-relevant value metrics, while simultaneously designing training curricula that reduce surgeon learning curves and facilitate uptake in ambulatory settings. Investment in post-market surveillance and real-world evidence platforms will help strengthen reimbursement arguments and maintain provider confidence.

Supply chain leaders must accelerate dual-sourcing strategies and evaluate near-shore manufacturing options to reduce exposure to tariff-induced cost shocks and logistics disruptions. Contracting teams should renegotiate terms with an eye to flexibility, incorporating volume-based tiers and shorter re-pricing windows to respond to rapid policy shifts. For distributors and health systems, aligning procurement cadence with device lifecycle stages and developing contingency inventory plans will preserve access and protect patient scheduling.

Clinician leaders and hospital administrators should collaborate to define clear patient selection criteria, standardize perioperative care pathways, and measure patient-reported outcomes to demonstrate comparative value. Finally, cross-sector stakeholders are advised to pursue targeted pilot programs that combine device deployment with economic modeling and outcomes tracking to catalyze payer discussions and build local evidence for broader adoption.

A rigorous, multi-source research approach combining primary clinical interviews, regulatory review, and iterative validation to ensure analytical reliability

The research methodology underpinning this analysis integrates triangulated evidence drawn from primary stakeholder engagement, targeted secondary review, and systematic validation protocols. Primary inputs included structured interviews with surgeons, operating room managers, procurement leaders, and device developers, designed to surface on-the-ground insights about device selection, procedural logistics, and reimbursement dynamics. These interviews were complemented by observational inputs from procedure workflows and training sessions to capture practical integration challenges that may not be visible in published literature.

Secondary research encompassed regulatory documentation, peer-reviewed clinical literature, and public filings to map device approvals, indications, and clinical endpoints. Where regulatory documents were limited, corroborative interviews and procedural observations helped contextualize approval timelines and post-market obligations. Data synthesis involved cross-referencing clinical outcomes with distribution patterns and procurement practices to identify consistent trends and outliers.

Quality assurance was maintained through iterative review cycles with domain experts, triangulation across independent sources, and a clear statement of limitations where data gaps exist. The methodology emphasizes transparency in provenance and reproducibility of analytical steps, and notes that while effort was made to incorporate a diverse set of perspectives, local regulatory idiosyncrasies and proprietary commercial arrangements may require supplemental, context-specific investigation for transactional decisions.

Synthesis of strategic imperatives emphasizing clinical relevance, supply chain resilience, and targeted evidence generation to secure long-term adoption

This executive summary synthesizes the strategic contours that now define minimally invasive glaucoma surgery devices: technological diversification across mechanisms, evolving clinical adoption across indications and surgical approaches, and the increasing importance of regionalized commercialization strategies. Stakeholders that align product design with pragmatic clinician needs, invest in outcome-focused evidence, and build resilient, flexible supply chains are best positioned to capture durable value.

The cumulative policy and market shifts of recent years have underscored the need for agility. Providers and manufacturers must continuously reassess operating assumptions in light of tariff exposure, shifting site-of-care economics, and payer expectations for demonstrated value. Importantly, the most successful strategies will integrate clinical, commercial, and operational levers-pairing device differentiation with scalable training, targeted evidence generation, and adaptive contracting.

Looking forward, the interplay between clinical innovation and distribution innovation will determine which technologies become standard of care and which remain niche. Companies and health systems that invest early in collaborative pilots, robust real-world evidence programs, and surgeon enablement will create the conditions for sustained adoption and improved patient outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Rapid rise in combined cataract and ab interno MIGS procedures for glaucoma management leading to streamlined surgical workflows
• 5.2. Commercial launch of drug-eluting suprachoroidal microstents offering sustained intraocular pressure control without daily drops
• 5.3. Growing surgeon preference for trabecular meshwork bypass stents driven by simplicity and favorable safety profile in early glaucoma
• 5.4. Increasing investment in smart intraoperative imaging integration to enhance precision of MIGS device placement and procedural outcomes
• 5.5. Expansion of reimbursement coverage for office-based MIGS treatments improving patient access in key developed markets
• 5.6. Development of next-generation bioresorbable implants aimed at reducing foreign body reactions and long-term tissue scarring
• 5.7. Surge in clinical trials evaluating combination therapies of MIGS devices with sustained-release pharmacologics for enhanced efficacy
• 5.8. Entry of emerging-market manufacturers offering cost-competitive MIGS alternatives spurring pricing pressure on established players

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Minimally Invasive Glaucoma Surgery Devices Market, by Mechanism

• 8.1. Introduction
• 8.2. Subconjunctival Filtration
• 8.3. Suprachoroidal Shunts
• 8.4. Trabecular Micro-Bypass
  • 8.4.1. Hydrus Microstent
  • 8.4.2. IStent
  • 8.4.3. Kahook Dual Blade
  • 8.4.4. Trabectome

9. Minimally Invasive Glaucoma Surgery Devices Market, by Indication

• 9.1. Introduction
• 9.2. Pediatric Glaucoma
• 9.3. Primary Open Angle Glaucoma
• 9.4. Secondary Glaucoma

10. Minimally Invasive Glaucoma Surgery Devices Market, by Surgical Approach

• 10.1. Introduction
• 10.2. Ab Externo
• 10.3. Ab Interno

11. Minimally Invasive Glaucoma Surgery Devices Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgery Centers
• 11.3. Hospital
• 11.4. Ophthalmic Clinics

12. Minimally Invasive Glaucoma Surgery Devices Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Offline
• 12.3. Online

13. Americas Minimally Invasive Glaucoma Surgery Devices Market

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. Argentina

14. Europe, Middle East & Africa Minimally Invasive Glaucoma Surgery Devices Market

• 14.1. Introduction
• 14.2. United Kingdom
• 14.3. Germany
• 14.4. France
• 14.5. Russia
• 14.6. Italy
• 14.7. Spain
• 14.8. United Arab Emirates
• 14.9. Saudi Arabia
• 14.10. South Africa
• 14.11. Denmark
• 14.12. Netherlands
• 14.13. Qatar
• 14.14. Finland
• 14.15. Sweden
• 14.16. Nigeria
• 14.17. Egypt
• 14.18. Turkey
• 14.19. Israel
• 14.20. Norway
• 14.21. Poland
• 14.22. Switzerland

15. Asia-Pacific Minimally Invasive Glaucoma Surgery Devices Market

• 15.1. Introduction
• 15.2. China
• 15.3. India
• 15.4. Japan
• 15.5. Australia
• 15.6. South Korea
• 15.7. Indonesia
• 15.8. Thailand
• 15.9. Philippines
• 15.10. Malaysia
• 15.11. Singapore
• 15.12. Vietnam
• 15.13. Taiwan

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Alcon Inc.
  • 16.3.2. Ellex Medical Lasers Ltd.
  • 16.3.3. AbbVie Inc.
  • 16.3.4. Bausch+Lomb France SAS
  • 16.3.5. Carl-Zeiss AG
  • 16.3.6. Corza Ophthalmology
  • 16.3.7. Glaukos Corporation
  • 16.3.8. I Optima Ltd.
  • 16.3.9. Iridex Corporation
  • 16.3.10. iSTAR Medical
  • 16.3.11. Johnson & Johnson Vision Care, Inc.
  • 16.3.12. Lumenis Be Ltd.
  • 16.3.13. New World Medical, Inc.
  • 16.3.14. Optonol Ltd.
  • 16.3.15. Santen Pharmaceutical Co., Ltd.
  • 16.3.16. Sight Sciences, Inc.
  • 16.3.17. Ziemer Ophthalmic Systems AG

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

• FIGURE 1. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET RESEARCH PROCESS
• FIGURE 2. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 3. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 4. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2024 VS 2030 (%)
• FIGURE 6. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
• FIGURE 8. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2024 VS 2030 (%)
• FIGURE 10. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 12. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 14. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 16. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 18. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 21. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 22. ASIA-PACIFIC MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 23. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 24. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024
• FIGURE 25. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET: RESEARCHAI
• FIGURE 26. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET: RESEARCHSTATISTICS
• FIGURE 27. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET: RESEARCHCONTACTS
• FIGURE 28. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET: RESEARCHARTICLES

LIST OF TABLES

• TABLE 1. MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, 2025-2030 (USD MILLION)
• TABLE 5. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 7. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 9. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 11. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUBCONJUNCTIVAL FILTRATION, BY REGION, 2025-2030 (USD MILLION)
• TABLE 13. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SUPRACHOROIDAL SHUNTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 15. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 17. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY HYDRUS MICROSTENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY HYDRUS MICROSTENT, BY REGION, 2025-2030 (USD MILLION)
• TABLE 19. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ISTENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ISTENT, BY REGION, 2025-2030 (USD MILLION)
• TABLE 21. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY KAHOOK DUAL BLADE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY KAHOOK DUAL BLADE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 23. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECTOME, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECTOME, BY REGION, 2025-2030 (USD MILLION)
• TABLE 25. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 27. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 29. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PEDIATRIC GLAUCOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PEDIATRIC GLAUCOMA, BY REGION, 2025-2030 (USD MILLION)
• TABLE 31. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PRIMARY OPEN ANGLE GLAUCOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY PRIMARY OPEN ANGLE GLAUCOMA, BY REGION, 2025-2030 (USD MILLION)
• TABLE 33. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SECONDARY GLAUCOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SECONDARY GLAUCOMA, BY REGION, 2025-2030 (USD MILLION)
• TABLE 35. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 37. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AB EXTERNO, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AB EXTERNO, BY REGION, 2025-2030 (USD MILLION)
• TABLE 39. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AB INTERNO, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AB INTERNO, BY REGION, 2025-2030 (USD MILLION)
• TABLE 41. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 43. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 45. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 47. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 49. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 51. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 53. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 55. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 56. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 57. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 58. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 59. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 60. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 61. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 62. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 63. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 64. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 65. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 66. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 67. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 68. AMERICAS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 69. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 70. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 71. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 72. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 73. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 74. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 75. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 76. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 77. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 78. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 79. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 80. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 81. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
• TABLE 82. UNITED STATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
• TABLE 83. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 84. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 85. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 86. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 87. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 88. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 89. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 90. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 91. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 92. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 93. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 94. CANADA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 95. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 96. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 97. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 98. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 99. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 100. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 101. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 102. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 103. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 104. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 105. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 106. MEXICO MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 107. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 108. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 109. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 110. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 111. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 112. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 113. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 114. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 115. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 116. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 117. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 118. BRAZIL MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 119. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 120. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 121. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 122. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 123. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 124. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 125. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 126. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 127. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 128. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 129. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 130. ARGENTINA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 136. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 137. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 138. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 139. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 140. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 141. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 142. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 143. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 146. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 147. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 148. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 150. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 151. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 152. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 153. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 154. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 155. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 156. UNITED KINGDOM MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 157. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 158. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 159. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 160. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 161. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 162. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 163. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 164. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 165. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 166. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 167. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 168. GERMANY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 169. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 170. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 171. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 172. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 173. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 174. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 175. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 176. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 177. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 178. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 179. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 180. FRANCE MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 181. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 182. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 183. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 184. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 185. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 186. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 187. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 188. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 189. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 190. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 191. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 192. RUSSIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 193. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 194. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 195. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 196. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 197. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 198. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 199. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 200. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 201. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 202. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 203. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 204. ITALY MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 205. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 206. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 207. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 208. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 209. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 210. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 211. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 212. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 213. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 214. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 215. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 216. SPAIN MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 217. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 218. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 219. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 220. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 221. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 222. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 223. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 224. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 229. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 230. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 231. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 232. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 233. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 234. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 235. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 236. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 238. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 240. SAUDI ARABIA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 241. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 242. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 244. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 246. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 248. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 249. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 251. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 252. SOUTH AFRICA MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 253. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 254. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 255. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 256. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)
• TABLE 257. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 258. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
• TABLE 259. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2018-2024 (USD MILLION)
• TABLE 260. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY SURGICAL APPROACH, 2025-2030 (USD MILLION)
• TABLE 261. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 262. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 263. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 264. DENMARK MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 265. NETHERLANDS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
• TABLE 266. NETHERLANDS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
• TABLE 267. NETHERLANDS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2018-2024 (USD MILLION)
• TABLE 268. NETHERLANDS MINIMALLY INVASIVE GLAUCOMA SURGERY DEVICES MARKET SIZE, BY TRABECULAR MICRO-BYPASS, 2025-2030 (USD MILLION)

TABLE 26